Women with PMOS at four-fold higher risk of heart disease

Women with polyendocrine metabolic ovarian syndrome (PMOS; also known as polycystic ovary syndrome or PCOS) face a fourfold higher risk of heart disease than women without PMOS, according to a new nationwide U.S. study published ...

Q&A: Psychedelics, cannabis, GLP-1s and drug policy changes

From headlines and social media, psychedelic therapies, cannabis use and GLP-1 medications have seemingly become commonplace overnight, but the science underlying these treatments and the pathway to drug approval are often ...

Researchers study barriers to GLP-1 insurance coverage

Despite growing evidence that GLP-1 medications improve health and are worth their cost, many insurance plans still limit coverage. University of Mississippi researchers are examining why and where that leaves patients.

page 2 from 40